Search Results 151-160 of 17147 for egfr
... [eGFR] <30 or on dialysis). This is a multicenter randomized controlled trial with a target randomization of ~1000 patients with advanced CKD and at least ...
Participation eligibility · pre-existing chronic kidney disease as defined by eGFR less than 60 ml/min/1.73 m2 · history of diabetes mellitus · requiring use of ...
... EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, and RET) and that has progressed on or after 1 or more kinase inhibitors and platinum-based chemotherapy.
... EGFR TKIs, such as erlotinib, gefitinib, or another EGFR TKI appropriate for the treatment of EGFR-mutant NSCLC. Patients known to have an ALK fusion ...
eGFR can be determined using the most recent serum creatinine value. A pre-existing diagnosis of ADPKD defined as follows: Evidence of polycystic kidney ...
The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients ...
with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0
eGfr and date. NB: If Yes to any of the details please inform the Imaging Department prior to the examination. REFERRING CLINICIAN DETAILS –IR(ME)R 2017 ...
- BRAF mutation mutant allele frequency (MAF) > 0.5%. - EGFR mutation (MAF > 0.5%). Note: EGFR S492R, K467, and R451C mutations are not an exclusion ...
Solid tumors. Amivantamab (Rybrevant) attaches to EGFR and MET proteins to treat certain types of non-small cell lung cancer. Tarlatamab (Imdelltra) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.